Back to search results

Sacituzumab Govitecan in Recurrent Glioblastoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Recurrent Glioblastoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States

    Contact: Study coordinator (Mina Lobbous, MD, MSPH) · lobboum@ccf.org · 216-445-3307
    Contact: Principal Investigator (Mina Lobbous, MD)

  • Texas Oncology Austin, Austin, Texas, United States

    Contact: Study coordinator (Brian Valliant, MD) · Brian.Vaillant@usoncology.com · (512) 421-4100
    Contact: Principal Investigator (Brian Valliant, MD)

  • University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center, San Antonio, Texas, United States

    Contact: Study coordinator (William Kelly, MD) · kellyw@uthscsa.edu · 210-450-1000
    Contact: Study coordinator (Epp Goodwin) · goodwine@uthscsa.edu
    Contact: Principal Investigator (William Kelly, MD)
Study leads

  • William Kelly, MD

    Principal Investigator

    Mays Cancer Center, UT Health San Antonio

View source on ClinicalTrials.gov(opens in a new tab)Contact study team (email)